Antengene Corporation Limited (6996.HK) announced that China National Medical ProductsAdministration or NMPA has approved the investigational new drug application for thePhase Ib/II CLINCH-2 study evaluating ATG-022 in combination with Merck & Co., Inc.'s anti-PD-1 therapy, KEYTRUDA, as well as ATG-022 in combination with pembrolizumab and chemotherapy.
Antengene Limited is a commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. To date, Antengene has obtained 32 IND approvals in the U.S. and Asia, and submitted NDAs in 11 Asia Pacific markets.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.